Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL14080529 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL28871763 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL3911371 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL406837 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL14861666 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL26432 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29431568 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL18497244 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL119382 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787913 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724537-A1 | COATING RESISTANT TO BIOGROWTH PARTICULARLY IN MARINE ENVIRONMENTS | Core Industries II, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| CN-119935993-A | Method for detecting medetomidine hydrochloride and analogues thereof by using metalloporphyrin | 广东工业大学 | 2025-05-06 | — | — | CN | claimed |
| EP-4506340-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Obshestvo s Ogranichennoj Otvetstvennostju "Vikzdorove Zhivotnyh" (RU) | 2025-02-12 | — | — | EP | claimed |
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | OBSHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU "VIK-ZDOROVE ZHIVOTNYKH" (RU) | 2025-01-23 | — | — | US | claimed |
| US-20240409755-A1 | COATING RESISTANT TO BIOGROWTH PARTICULARLY IN MARINE ENVIRONMENTS | CORE INDUSTRIES II, LLC | 2024-12-12 | — | — | US | claimed |
| WO-2024254171-A1 | COATING RESISTANT TO BIOGROWTH PARTICULARLY IN MARINE ENVIRONMENTS | CORE INDUSTRIES II, LLC (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2023182903-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Общество с ограниченной ответственностью "ВИК-здоровье животных" | 2023-09-28 | — | — | WO | claimed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| US-20170304387-A1 | NEW INDICATION OF ANTIBIOTIC DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| US-9339498-B2 | Sedating and immobilizing non-domesticated mammals | WILDLIFE LABORATORIES, INC. (US) | 2016-05-17 | — | — | US | claimed |
| US-20150290186-A1 | Sedating and Immobilizing Non-Domesticated Mammals | WILDLIFE LABORATORIES, INCORPORATED (US) | 2015-10-15 | — | — | US | claimed |
| US-7795263-B2 | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals | WILDLIFE LABORATORIES, INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-20100010006-A1 | Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals | WILDLIFE LABORATORIES, LLC | 2010-01-14 | — | — | US | claimed |
| WO-2009053709-A1 | PROCESS FOR THE PREPARATION OF MEDETOMIDINE | NORBROOK LABORATORIES LIMITED (GB) | 2009-04-30 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20030013692-A1 | Methods of treating neurological disorders | GULLANS STEVEN R (US) | 2003-01-16 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2002056892-A2 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-07-25 | — | — | WO | claimed |
| EP-4743129-A1 | BONE SUBSTITUTE MATERIAL BASED ON CALCIUM SILICATE AND CALCIUM PHOSPHATE | Septodont ou Septodont SAS ou Spécialités Septodont (FR) | 2026-05-20 | — | — | EP | disclosed |
| WO-1996028551-A1 | VACCINES FOR PLAGUE | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | ADRB2, OPRM1, ADRA2C | ADRA2A 9/4885ADRA2B 5/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.